Compare QUALCOMM, Inc. (QCOM) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
QUALCOMM, Inc. vs Zimmer Biomet Holdings Inc — how do they compare? QUALCOMM, Inc. trades at $172.9 (market cap $187.95B), while Zimmer Biomet Holdings Inc trades at $88.9 (market cap $16.95B). The key difference: QUALCOMM, Inc. is far larger — about 11.1× Zimmer Biomet Holdings Inc's market cap, and QUALCOMM, Inc. pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold QUALCOMM, Inc. for 87 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| QCOM | ZBH | |
|---|---|---|
Market Cap | $187.95B | $16.95B |
Volume | 9,535,042 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $251.10 | $103.98 |
52-Week Low | $124.07 | $79.58 |
Typical Hold Time | 87 Days | 89 Days |
Enterprise Value | $194.92B | $24.02B |
Dividend Yield | 2.09% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Qualcomm (QCOM) trades at $177.06, down 2.21% today, with a bearish technical signal and support near $175. The company reported strong revenue of $44.28B in 2025 but net income fell to $5.54B, reflecting margin pressure. Recent news highlights a strategic AI partnership with Amazon, potentially opening a $60B opportunity, while analyst consensus remains mixed with a $204.48 price target.
QCOM's outlook is balanced by AI growth potential against near-term headwinds. The Amazon deal and diversification into automotive and data centers offer upside, but execution risks, competition, and dependence on smartphone markets pose challenges. Valuation metrics like a P/E of 20.12 appear reasonable if AI initiatives accelerate revenue.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal despite recent earnings beats. The company shows steady revenue growth to $8.23B in 2025, though net margins have compressed from 13.84% in 2023 to 8.56%. Analyst consensus is mixed with 40% buy ratings but a $103.11 price target suggesting 16.5% upside. Recent news highlights dividend declarations and leadership promotions aimed at accelerating commercial transformation.
ZBH presents a value opportunity with reasonable valuation multiples (P/E 21.48, P/S 2.04) and consistent earnings outperformance, but faces headwinds from margin pressure and technical weakness. The stock's investment case hinges on execution of growth initiatives amid competitive and debt-related risks, with current levels offering entry near support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
